Skip to main content
. Author manuscript; available in PMC: 2016 Feb 28.
Published in final edited form as: Lancet. 2014 Nov 16;385(9970):792–798. doi: 10.1016/S0140-6736(14)62052-3

Figure 3. Bayesian meta-analysis of cardiovascular and non-cardiovascular mortality associated with extended duration DAPT versus short duration or no DAPT.

Figure 3

Figure 3

Hazard ratio for cardiovascular mortality (A), and non-cardiovascular mortality (B). Results are presented prior to and after inclusion of the DAPT Study.3 The number of cardiovascular deaths in the CASPAR trial was not reported and is therefore not reflected in the total event count.11 DAPT=dual antiplatelet therapy. HR=hazard ratio.